This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
CHICAGO – Gallium-68 (Ga-68) RM2-PET/MRI is better than MRI alone for detecting relapse in prostate cancer patients, according to research presented November 26 at RSNA 2023. ng/mL after prostatectomy or ≥ 2 ng/mL after radiotherapy) and negative conventional imaging (CT and/or bonescans).
Nuclearmedicine is a form of specialty medicine that uses radioactive tracers to evaluate bodily functions and to diagnose and treat a wide range of health conditions. Nuclearscans produce images of the body’s anatomy that cannot be obtained as clearly or fully with other imaging techniques.
PET/CT imaging with a new gallium-68-based prostate cancer radiotracer shows promise for detecting recurrent metastatic disease, according to a study published February 20 in the Journal of NuclearMedicine. Images and caption courtesy of the Journal of NuclearMedicine. HU = Houndsfield unit; SUVbw = body-weight SUV.
There are several types of imaging tests that physicians use to detect cancer in patients: X-Ray, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Ultrasound (US), NuclearMedicine, and Positron Emission Tomography (PET).
PET/CT imaging with a new radiotracer (F-18 PSMA-1007) is superior to MRI prior to surgery in men with intermediate-risk and high-risk prostate cancer, according to a study published on July 1 in JAMA Oncology. In this phase II clinical trial, the researchers sought to evaluate the approach further.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content